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Abstract
Introduction Fibroblast-like synoviocytes (FLS) from
rheumatoid arthritis (RA) patients share many similarities with
transformed cancer cells, including spontaneous production of
matrix metalloproteinases (MMPs). Altered or chronic activation
of proto-oncogenic Ras family GTPases is thought to contribute
to inflammation and joint destruction in RA, and abrogation of
Ras family signaling is therapeutic in animal models of RA.
Recently, expression and post-translational modification of Ras
guanine nucleotide releasing factor 1 (RasGRF1) was found to
contribute to spontaneous MMP production in melanoma
cancer cells. Here, we examine the potential relationship
between RasGRF1 expression and MMP production in RA,
reactive arthritis, and inflammatory osteoarthritis synovial tissue
and FLS.
Methods Expression of RasGRF1, MMP-1, MMP-3, and IL-6
was detected in synovial tissue by immunohistochemistry and
stained sections were evaluated by digital image analysis.
Expression of RasGRF1 in FLS and synovial tissue was also
assessed by immunoblotting. Double staining was performed to
detect proteins in specific cell populations, and cells producing
MMP-1 and MMP-3. RasGRF1 expression was manipulated in
RA FLS by cDNA transfection and gene silencing, and effects
on MMP-1, TIMP-1, MMP-3, IL-6, and IL-8 production measured
by ELISA.
Results Expression of RasGRF1 was significantly enhanced in
RA synovial tissue, and detected in FLS and synovial
macrophages in situ. In cultured FLS and synovial biopsies,
RasGRF1 was detected by immunoblotting as a truncated
fragment lacking its negative regulatory domain. Production of
MMP-1 and MMP-3 in RA but not non-RA synovial tissue
positively correlated with expression of RasGRF1 and co-
localized in cells expressing RasGRF1. RasGRF1
overexpression in FLS induced production of MMP-3, and
RasGRF1 silencing inhibited spontaneous MMP-3 production.
Conclusions Enhanced expression and post-translational
modification of RasGRF1 contributes to MMP-3 production in
RA synovial tissue and the semi-transformed phenotype of RA
FLS.
Introduction
Inflammation of affected joints in rheumatoid arthritis (RA) is
characterized by infiltration of the synovial sublining by macro-
phages, lymphocytes, and other immune cells, and by intimal
lining layer hyperplasia due to increased numbers of intimal
macrophages and fibroblast-like synoviocytes (FLS) [1]. Initial
in situ and in vitro studies of invasive RA FLS revealed striking
similarities with transformed cells expressing mutated proto-
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oncogene and tumor suppressor gene products [2]. Hyper-
plastic FLS invading the joints of RA patients resemble prolif-
erating tumor cells, and RA FLS proliferate more rapidly in vitro
than FLS from inflammatory non-RA patients or healthy individ-
uals [3]. Characteristic of transformed cells, RA FLS sponta-
neously secrete autocrines and matrix metalloproteinases
(MMPs), display anchorage-independent growth, and are
resistant to contact inhibition of proliferation [4,5]. While trans-
forming mutations in gene products involved in cellular trans-
formation, such as Ras and PTEN, have not been detected in
RA FLS [6,7], it is appreciated that signaling pathways regu-
lated by proto-oncogene and tumor suppressor gene prod-
ucts are constitutively activated due to stimulation by
inflammatory cytokines, chemokines, growth factors, and oxi-
dative stress in RA synovial tissue [8].
Ras superfamily small GTPases are expressed throughout
mammalian tissue, and play essential roles in coupling extra-
cellular stimuli to multiple downstream signaling pathways [9].
Cellular stimulation results in the activation of guanine nucle-
otide exchange factors (GEFs), which catalyze the exchange
of GDP on inactive GTPase for GTP. The binding of GTP to
Ras superfamily GTPases leads to a conformational change in
the GTPase, allowing signaling to downstream effector pro-
teins [10]. Of these small GTPases, Ras family homologs (H-
Ras, K-Ras, and N-Ras) are important in coupling extracellular
stimuli to activation of a shared set of signaling pathways reg-
ulating cell proliferation and survival, including mitogen-acti-
vated protein kinase cascades, phosphoinositide 3-kinase and
Ral GTPases [9,11]. The related but distinct family of Rho
GTPases (including Rac, Cdc42 and Rho proteins) regulate
cellular polarization and chemotactic responses, mitogen-acti-
vated protein kinase cascades, and oxidative burst machinery
[12,13]. GEF selectivity in activating different Ras homologs,
as well as differential coupling of GEFs to specific types of cel-
lular receptors – such as Son-of-sevenless coupling to tyro-
sine kinase-dependent receptors, and Ras guanine
nucleotide-releasing factor 1 (RasGRF) coupling to G protein-
coupled receptors – achieve specificity in Ras superfamily
GTPase signaling.
Previous studies have demonstrated that Ras family homologs
are present in RA synovial tissue, and are preferentially
expressed in the intimal lining layer [14,15]. Activation of Ras
effector pathways, including mitogen-activated protein
kinases, phosphoinositide 3-kinase, and NF-κB, is enhanced
in RA patients compared with disease control individuals [16-
18]. In RA synovial fluid T cells, constitutive activation of Ras,
in conjunction with inactivation of the related GTPase Rap1,
contributes to persistent reactive oxygen species production
by these cells [19,20]. In RA FLS, ectopic expression of dom-
inant-negative H-Ras suppresses IL-1-induced extracellular
signal-regulated kinase activation and IL-6 production [21].
Dominant-negative Raf kinase, which broadly binds to and
inhibits Ras family members and related GTPases, sup-
presses epidermal growth factor-induced extracellular signal-
regulated kinase and c-jun N-terminal kinase (JNK) activation
in RA FLS, and reduces constitutive expression of MMPs [22].
Additionally, strategies that broadly inhibit Ras family function
in vivo are protective in animal models of arthritis [21-23].
Evidence is now emerging that altered expression of Ras
GEFs may contribute to autoimmune diseases. Mice lacking
expression of the Ras GEF Ras guanine nucleotide-releasing
protein 1 develop a spontaneous systemic lupus erythemato-
sus-like disease, and similar defects are observed in a subset
of systemic lupus erythematosus patients [24-26]. Recent evi-
dence has shown that expression levels of the GEF RasGRF1
regulate constitutive MMP-9 production in human melanoma
cells [27]. RasGRF1 displays in vitro and in vivo exchange
activity against H-Ras [28], as well as against the Rho family
GTPase Rac [29,30]. RasGRF1 activity can also be regulated
by protease-dependent post-translational modification, as cal-
pain-dependent cleavage of RasGRF1 enhances its Ras-acti-
vating capacity in vitro and in vivo [31]. Given the similarities
between FLS and transformed cancer cells, we examined the
expression of RasGRF1 in RA and non-RA synovial tissue and
FLS, providing evidence that elevated RasGRF1 expression
and post-translational modification of this protein in RA syno-
vial tissue may contribute to joint destruction by stimulating
MMP-3 production.
Materials and methods
Patients and synovial tissue samples
Synovial biopsy samples were obtained by arthroscopy, as
previously described [32], from an actively inflamed knee or
ankle joint, defined by both pain and swelling, of patients with
RA (n = 10) [33], with reactive arthritis (ReA) (n = 107) [34],
or with inflammatory osteoarthritis (OA) (n = 104) [35]. Patient
characteristics are detailed in Table 1. All patients provided
written informed consent prior to the start of the present study,
which was approved by the Medical Ethics Committee of the
Academic Medical Center, University of Amsterdam, The
Netherlands.
Immunohistochemical analysis
Serial sections from at least six different biopsy samples per
patient were cut with a cryostat (5 μm) and fixed with acetone,
and the endogenous peroxidase activity was blocked with
0.3% hydrogen peroxide in 0.1% sodium azide/PBS. Sections
were stained overnight at 4°C with mAbs against MMP-1
(MAB 1346) and against MMP-3 (MAB 1339) (both from
Chemicon International, Temicula, CA, USA) and with rabbit
polyclonal antibodies recognizing RasGRF1 (SC-863) (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), and anti-IL-6
(Department of Nephrology, Leiden University Medical Center,
Leiden, The Netherlands). For control sections, primary anti-
bodies were omitted or irrelevant immunoglobulins were
applied.Available online http://arthritis-research.com/content/11/4/R121
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Sections were then washed and incubated with goat anti-
mouse horseradish peroxidase (HRP)-conjugated antibodies
or swine anti-rabbit-HRP-conjugated antibodies (Dako, Glos-
trup, Denmark), followed by incubation with biotinylated tyra-
mide and streptavidin–HRP, and development with amino-
ethylcarbazole (Vector Laboratories, Burlingame, CA, USA)
[36]. Sections were then counterstained with Mayer's hema-
toxylin (Perkin Elmer Life Sciences, Boston, MA, USA) and
mounted in Kaiser's glycerol gelatin (Merck, Darmstadt,
Germany).
Digital image analysis
For quantitative analysis of protein expression, stained slides
were randomly coded by an independent observer, blinded to
antibodies used and clinical diagnosis. Stained sections were
analyzed by computer-assisted image analysis using the Qwin
analysis system (Leica, Cambridge, UK) as previously
described in detail [37]. Values of integrated optical densities/
mm2 and the number of positive cells/mm2 were obtained for
both the intimal lining layer and the synovial sublining, and
were corrected for total number of nucleated cells/mm2.
Immunohistochemical double staining
To detect potential cell-specific expression of RasGRF1 in
synovial tissue, tissue sections were incubated with anti-
RasGRF1 antibodies overnight at 4°C, followed by serial incu-
bation with swine anti-rabbit-HRP antibodies, biotinylated
tyramine, and streptavidin–HRP. Sections were then labeled
for 1 hour at room temperature with FITC-conjugated antibod-
ies to detect T lymphocytes (anti-CD3, clone SK7; Becton
Dickinson, San Jose, CA, USA), FLS (anti-CD55, mAB67;
Serotec, Oxford, UK), and macrophages (anti-CD68, clone
DK25; Dako), followed by incubation with alkaline phos-
phatase-conjugated goat anti-mouse antibody (Dako). HRP
staining was developed as above, and alkaline phosphatase
staining was developed using an AP Substrate III kit (SK-
5300; Vector Laboratories) according to the manufacturer's
instructions.
Fibroblast-like synoviocyte culture and transfection with 
cDNA and locked nucleic acids
RA FLS and OA FLS were cultured as previously described
[38]. FLS were used between passages 4 and 9 and were cul-
tured in medium containing 10% FCS. To examine the influ-
ence of RasGRF1 overexpression on FLS MMP production, 2
× 105 RA FLS were plated overnight in six-well plates and
were then transfected with 7.5 μg control pCDNA3 or
pCDNA3 encoding full-length human RasGRF1 (provided by
Dr R. Zippel, University of Milan, Milan, Italy) using Lipo-
fectamine 2000 transfection reagent (Invitrogen, Verviers, Bel-
gium) as per the manufacturer's instructions. Culture medium
was replaced with medium containing 1.0% FCS after 24
hours, and cells were harvested 48 hours post-transfection.
RasGRF1 expression in FLS was silenced using RasGRF1-
specific and control locked nucleic acids (LNA) designed with
online software [39] (synthesized by Exiqon A/S, Vedbaek,
Denmark). The LNA oligonucleotides used were RasGRF1
Table 1
Clinical features of rheumatoid arthritis, reactive arthritis and osteoarthritis patients included in the study
Diagnosis Characteristic Median (range)
Rheumatoid arthritis Age (years) 55 (30 to 68)
Male:female 6:4
Disease duration (months) 84 (2 to 360)
Erythrocyte sedimentation rate (mm/hour) 64 (2 to 107)
Rheumatoid factor 21 (0 to 138)
Reactive arthritis Age (years) 33 (22 to 39)
Male:female 4:3
Disease duration (months) 2.5 (1 to 14)
Erythrocyte sedimentation rate (mm/hour) 5 (0 to 14)
Rheumatoid factor 0 (0 to 1)
Osteoarthritis Age (years) 72.5 (54 to 83)
Male:female 2:2
Disease duration (months) 66 (6 to 180)
Erythrocyte sedimentation rate (mm/hour) 9.5 (5 to 43)
Rheumatoid factor 0 (0 to 1)Arthritis Research & Therapy    Vol 11 No 4    Abreu et al.
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(TTGcgttaccttTGCt – LNA nucleotides in uppercase letters,
DNA nucleotides in lowercase letters), and as a negative con-
trol we used a scrambled RasGRF1 sequence (GTAcagcaa-
gatTGGg). LNA transductions were performed with
Lipofectamine 2000 transfection reagent and 50 nM LNA.
Culture medium was replaced with starvation medium (1%
FCS in DMEM) after 24 hours and cells were harvested after
an additional 24 hours.
Protein preparation and immunoblotting
FLS were lysed in Laemli's buffer. Frozen synovial biopsies
were homogenized and proteins were solubilized using a
ReadyPrep™ Sequential Extraction Kit (BioRad, Hercules, CA,
USA). The protein content was quantified using a BCA Protein
Assay Kit (Pierce, Rockford, IL, USA). Equivalent amounts of
protein were resolved by electrophoresis on NuPage 4 to 12%
Bis–Tris gradient gels (Invitrogen) and were transferred to pol-
yvinylidene difluoride membrane (BioRad). Proteins were
detected by immunoblotting with anti-RasGRF1 antibodies
(SC-863 and SC-224; Santa Cruz), actin antibodies (Santa
Cruz) or tubulin antibodies (Sigma Aldrich, St Louis, MO,
USA), followed by extensive washing, incubation with HRP-
conjugated anti-rabbit or anti-mouse immunoglobulin antibod-
ies (BioRad) and enhanced chemiluminescence detection
(Pierce). For quantitative analysis of RasGRF1 expression,
staining was detected using IRDye 680-labeled or 800-
labeled antibodies and an Odyssey Imager (LI-COR, Bad
Homburg, Germany), and was quantified using Odyssey 3.0
software.
Measurement of MMP-1, MMP-3, TIMP-1, IL-6 and IL-8 
production by fibroblast-like synoviocytes
Medium was removed from FLS 24 hours after introduction of
cDNA or LNA, and was replaced with starvation medium. After
24 hours, cell-free tissue culture supernatants were harvested
and analyzed using ELISA kits for MMP-1, MMP-3, TIMP-1 (all
from R&D Systems Europe Ltd, Abingdon, UK), IL-6 and IL-8
(both from Sanquin Reagents, Amsterdam, The Netherlands),
according to the manufacturers' instructions.
Immunofluorescence staining
Synovial tissue sections were incubated with primary anti-
RasGRF1 antibodies overnight at 4°C, followed by incubation
for 30 minutes with Alexa-594-conjugated goat anti-rabbit
antibodies (Molecular Probes Europe, Leiden, the Nether-
lands). Sections were then incubated with mouse monoclonal
antibodies against MMP-1, MMP-3, or IL-6, followed by incu-
bation with Alexa-488-conjugated goat anti-mouse antibody
(Molecular Probes Europe), mounting in Vectashield (Vector
Laboratories) and analysis using a fluorescence microscope
(Leica DMRA) coupled to a CCD camera and Image-Pro Plus
software (Media Cybernetics, Dutch Vision Components,
Breda, the Netherlands).
Statistical analysis
Wilcoxon's nonparametric signed ranks test was used to com-
pare protein expression between the intimal lining layer and
the synovial sublining layer within diagnostic groups. As no
trend towards a difference in RasGRF1 expression was found
between inflammatory OA and ReA synovial tissues, these two
nonerosive groups were combined as non-RA samples for fur-
ther analyses. The Mann–Whitney U test was used for the
comparison of RasGRF1 expression between diagnostic
groups. Correlations between RasGRF1 expression and
MMP-1, MMP-3 and IL-6 expression in synovial tissue were
assessed by Spearman's rank correlation coefficient. ELISA
results were examined using Student's t test. P < 0.05 was
considered statistically significant. There was no correction for
multiple comparisons due to the exploratory nature of the
study.
Results
Expression of RasGRF1 in RA and non-RA synovial 
tissue
To gain insight into potential involvement of RasGRF1 in RA,
immunohistochemical staining was performed on RA synovial
tissue using RasGRF1-specific antibodies. While no specific
staining was observed with irrelevant control rabbit antibodies,
robust staining was observed in RA synovial tissue with anti-
RasGRF1 antibodies (Figure 1a). RasGRF1 staining was
most apparent throughout the intimal lining layer, but was also
observed in infiltrating mononuclear cells found in the synovial
sublining.
Initial qualitative analysis of RasGRF1 expression in RA and
inflammatory OA synovial tissue suggested that RasGRF1
expression was elevated in RA synovial tissue (Figure 1b). We
therefore compared RasGRF1 expression in RA and non-RA
(inflammatory OA and ReA) synovial tissue quantitatively,
using digital image analysis (Figure 1c). Preliminary analyses
indicated no differences in RasGRF1 expression between
inflammatory OA and ReA synovial tissue, either in the intimal
lining layer (mean integrated optical density/mm2 ± standard
error of the mean: OA, 259.0 ± 131.6; ReA, 263.4 ± 77.0) or
in the synovial sublining layer (OA, 113.3 ± 55.7; ReA, 135.6
± 51.9) (data not shown). These two non-erosive groups were
therefore combined as non-RA for further analyses. Compar-
ing RA with non-RA synovial tissue, RasGRF1 expression was
elevated in the RA (P < 0.05) and in the non-RA (P < 0.01)
intimal lining layer as compared with the synovial sublining.
RasGRF1 expression was enhanced in the synovial sublining
of RA tissue as compared with non-RA synovial tissue (P <
0.01), and a trend towards enhanced RasGRF1 expression
was observed in the RA intimal lining layer. Correction of
RasGRF1 expression for the number of RasGRF1-positive
cells confirmed that RasGRF1 expression was enhanced in
both the synovial sublining (P < 0.005) and the intimal lining
layer (P  < 0.05) of RA patients compared with non-RA
patients (data not shown).Available online http://arthritis-research.com/content/11/4/R121
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Qualitative double-labeling of RA synovial tissue with antibod-
ies recognizing RasGRF1 and markers for T lymphocytes
(CD3), FLS (CD55), and macrophages (CD68) revealed that
RasGRF1 expression was restricted to FLS and macrophages
(Figure 2).
RasGRF1 expression in RA and non-RA fibroblast-like 
synoviocytes
To independently confirm RasGRF1 expression in synovial tis-
sue and FLS detected by immunohistochemistry, we per-
formed immunoblotting experiments on lysates derived from
intact RA and OA synovial biopsies, and from RA and OA FLS.
Figure 1
Detection of RasGRF1 protein expression in rheumatoid arthritis and non-rheumatoid arthritis synovial tissue Detection of RasGRF1 protein expression in rheumatoid arthritis and non-rheumatoid arthritis synovial tissue. (a) Representative staining of rheuma-
toid arthritis (RA) synovial tissue with control and anti-Ras guanine nucleotide-releasing factor 1 (anti-RasGRF1) antibodies. (b) Representative 
staining of RA and osteoarthritis (OA) synovial tissue with anti-RasGRF1 antibodies. Staining was developed with amino-ethylcarbazole (red), and 
was counterstained with Mayer's hematoxylin. Magnification × 100. (c) Quantitative analysis of Ras signaling protein expression in RA and non-RA 
(OA and reactive arthritis) synovial tissue. Integrated optical densities (IOD)/mm2, corrected for nucleated cells, for staining of the synovial sublining 
(sub) and intimal lining (lin) layer of 10 RA patients and 11-non-RA (four inflammatory OA, seven reactive arthritis) patients with anti-RasGRF1 anti-
bodies. IOD values were calculated by computer-assisted image analysis. Box plots, 25th to 75th percentiles; lines within each box, median; lines 
outside boxes, 10th and 90th percentiles. Bars indicate statistically significant differences in protein expression between sublining and intimal lining 
layer tissues within diagnostic groups and between diagnostic groups. *P < 0.05, **P < 0.01, ***P < 0.005.Arthritis Research & Therapy    Vol 11 No 4    Abreu et al.
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In protein lysates derived from intact RA and OA synovial biop-
sies (Figure 3), we were unable to detect full-length 140 kDa
RasGRF1. We did, however, observe prominent expression of
a 98 kDa truncation product, and lower and variable levels of
75 and 54 kDa truncation products. These C-terminal frag-
ments are thought to be generated by calpain-dependent
cleavage, resulting in constitutive activation of RasGRF1
[27,31].
In analyses of FLS lysates, full-length 140 kDa RasGRF1 was
detected by immunoblotting in only one of six RA FLS lines
(RA FLS5), and in neither of two OA FLS lines tested (Figure
4a). In contrast, a 54 kDa RasGRF1 C-terminal fragment was
detected in all RA and OA FLS lines, a 75 kDa fragment in
three of five RA FLS lines and in both OA FLS lines, and a 98
kDa C-terminal fragment in four of six RA lines and in both OA
lines. Quantitative analysis of RasGRF1 protein expression in
five RA lines and five OA FLS lines revealed no significant dif-
ference in total RasGRF1 expression (Figure 4b). With the
exception of the 74 kDa RasGRF1 fragment, which was
detected at lower levels in RA FLS (P  < 0.05), the other
RasGRF1 truncation fragments, as well as full-length
RasGRF1, were expressed at similar levels in RA FLS and OA
FLS.
To verify that the observed truncation products were derived
from RasGRF1, rather than from nonspecific interactions with
the antibodies, we performed additional experiments. First, RA
FLS were transfected with cDNA encoding full-length
RasGRF1 (Figure 4c, d). Quantitative analysis of proteins
detected by immunoblotting demonstrated that transfection of
RA FLS with RasGRF1 cDNA encoding full-length RasGRF1
resulted in the enhanced expression of the 140 kDa (P <
0.01), 98 kDa and 75 kDa (P < 0.05), and 54 kDa (P < 0.05)
forms of RasGRF1. Second, we silenced RasGRF1 expres-
sion by transduction of RA FLS with RasGRF1-specific LNA.
LNA are antisense nucleotide analogs containing methylene
bridges that mimic the RNA monomer structure, and disrupt
gene expression by promoting mRNA degradation and/or pre-
venting gene product translation [40]. RasGRF1-specific LNA
decreased RasGRF1 expression in RA FLS compared with
control scrambled LNA (Figure 4e), while leaving tubulin
expression unaffected. Significant decreases in the expression
of full-length 140 kDa RasGRF1 (P < 0.05) and of the 98 kDa
(P < 0.01), 75 kDa (P < 0.05) and 54 kDa (P < 0.01) forms
were achieved (Figure 4f). Exposure of FLS to transfection rea-
gent alone resulted in the generation of an additional 60 kDa
polypeptide (mock-treated FLS in Figures 4c and 4e, asterisk)
not observed in synovial biopsies or untreated FLS, possibly
due to activation of an unidentified cellular protease.
Figure 2
Representative double staining of rheumatoid arthritis synovial tissue with antibodies against RasGRF1 and cell-specific markers Representative double staining of rheumatoid arthritis synovial tissue with antibodies against RasGRF1 and cell-specific markers. Synovial tissue 
sections were stained overnight with antibodies against Ras guanine nucleotide-releasing factor 1(RasGRF1), followed by antibodies against CD3, 
CD55, and CD68. After biotin tyramide enhancement, staining was developed with amino-ethylcarbazole (red, RasGRF1) and Fast blue (blue, cell-
specific markers). Magnification × 100.
Figure 3
RasGRF1 is expressed as a truncated protein in synovial tissue RasGRF1 is expressed as a truncated protein in synovial tissue.  Immu-
noblot analysis of Ras guanine nucleotide-releasing factor 1 
(RasGRF1) and actin in rheumatoid arthritis (RA) and osteoarthritis 
(OA) synovial biopsy lysates. The 98 kDa, 75 kDa and 54 kDa proteins 
reacting with RasGRF1 antibodies, and the expected position of full-
length 140 kDa RasGRF1, are indicated on the left by arrowheads. Rel-
ative mobility of molecular weight (Mw) standards (kDa) indicated to 
the right.Available online http://arthritis-research.com/content/11/4/R121
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Effects of changes in RasGRF1 expression on RA 
fibroblast-like synoviocyte MMP-3 production in vitro
As RasGRF1 expression levels regulate MMP production in
cancer cell lines [27], we examined whether modulation of
RasGRF1 expression in RA FLS might also regulate constitu-
tive MMP and cytokine production. Quantitative analysis of
FLS tissue culture supernatants demonstrated that RasGRF1
overexpression had no effect on FLS production of MMP-1
(Figure 5a) or of TIMP-1 (Figure 5b). Additionally, the ratio of
TIMP-1 expression relative to MMP-1 was unaffected (Figure
5c). Forced expression of RasGRF1, however, induced an
approximately 150% increase in MMP-3 production (mean ±
standard error of the mean, 27.99 ± 5.62 ng/ml) compared
with FLS transfected with empty control vector alone (11.47 ±
2.02 ng/ml) (P  < 0.05) (Figure 5d). Enhancing RasGRF1
expression had no effect on spontaneous IL-6 production by
RA FLS (Figure 5e), but did increase spontaneous IL-8 secre-
tion by approximately twofold (P < 0.05) (Figure 5f).
To determine whether RasGRF1 was required for spontane-
ous MMP or cytokine production, we silenced RasGRF1 gene
expression using LNA. Again, modulation of RasGRF1 expres-
sion failed to influence MMP-1 and TIMP-1 production, or the
ratio of TIMP-1 relative to MMP-1 (Figure 6a to 6c). A signifi-
Figure 4
RasGRF1 is expressed as a truncated protein in fibroblast-like synoviocytes RasGRF1 is expressed as a truncated protein in fibroblast-like synoviocytes.  (a) Immunoblot analysis of Ras guanine nucleotide-releasing factor 1 
(RasGRF1) in rheumatoid arthritis (RA) and osteoarthritis (OA) fibroblast-like synoviocytes (FLS). The 140 kDa, 98 kDa, 75 kDa and 54 kDa proteins 
reacting with RasGRF1 antibodies are indicated on the left by arrowheads. Relative mobility of molecular weight (Mw) standards (kDa) indicated to 
the right. (b) Expression of 140 kDa, 98 kDa, 75 kDa, and 54 kDa RasGRF1 polypeptides as well as the total RasGRF1 signal, normalized to tubulin 
expression, was quantified in RA (n = 5) and OA (n = 5) FLS lines, and expressed as mean optical density ± standard error of the mean (SEM). (c) 
Overexpression of RasGRF1 in RA FLS. RA FLS were treated with transfection reagent alone (mock) or transfected with empty (control) vector or 
vector encoding RasGRF1, and cell lysates immunoblotted with antibodies against RasGRF1 (upper panel) and tubulin (lower panel). Expression of 
full-length and truncated RasGRF1 polypeptides is indicated with arrows, and a 60 kDa polypeptide with an asterisk. (d) Expression of 140 kDa, 98 
kDa, 75 kDa, and 54 kDa RasGRF1 polypeptides following transfection of RA FLS with empty vector or RasGRF1, normalized to tubulin expression 
was quantified and expressed as mean optical density ± SEM (middle panel) (n = 4). (e) Silencing of RasGRF1 expression with locked nucleic acid 
(LNA). RA FLS were treated with transfection reagent alone (mock) or transduced with control or RasGRF1 LNA and lysates assessed for expres-
sion of RasGRF1 (upper panel) and tubulin (lower panel) by immunoblotting. (f) Quantitative analysis of (e) as in (d). *P < 0.05, **P < 0.01 com-
pared with controls.Arthritis Research & Therapy    Vol 11 No 4    Abreu et al.
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cant suppression of spontaneous MMP-3 production was
observed in tissue culture supernatants of FLS transduced
with RasGRF1-specific LNA (Figure 6d) (P < 0.05), as com-
pared with FLS treated with transfection reagent alone or in
combination with control scrambled LNA. Although overex-
pression of RasGRF1 in RA FLS failed to enhance basal IL-6
production (Figure 5e), IL-6 levels were significantly
decreased following silencing of RasGRF1 expression (Figure
6e) (P < 0.05). An apparent 67% reduction in spontaneous IL-
8 production was also noted, but this did not reach statistical
significance (P = 0.069) (Figure 6f).
Relationship between RasGRF1 expression and matrix 
metalloproteinase production in RA synovial tissue
Our in vitro data indicated an important role for RasGRF1 in
regulating MMP-3 expression in RA FLS. We therefore exam-
ined whether expression of RasGRF1 was associated with
MMP-3 production in RA synovial tissue. Immunohistochemi-
cal analysis demonstrated that MMP-1, MMP-3, and IL-6 were
readily detected in RA synovial tissue (Figure 7a). RasGRF1
expression demonstrated a strong positive correlation (R =
0.81, P = 0.022) with MMP-1 in the RA synovial sublining, but
not in the intimal lining layer (Figure 7b). Instead, a positive cor-
relation between RasGRF1 and MMP-3 expression was
observed in the intimal lining layer (R = 0.70, P = 0.043). In
non-RA patients, no significant association between
RasGRF1 and MMP-1 (synovial sublining: R  = 0.17, P  =
0.703; intimal lining layer: R = -0.89, P = 0.083) or MMP-3
(synovial sublining: R = 0.83, P = 0.058; intimal lining layer: R
= -0.20, P  = 0.917) expression was observed (data not
shown). No correlation was observed between RasGRF1
expression and IL-6 expression in either RA or non-RA patient
cohorts (Figure 7b and data not shown).
Double immunofluorescent staining revealed colocalization of
RasGRF1 with MMP-1 and MMP-3 in RA synovial tissue (Fig-
ure 8). Colocalization of RasGRF1 with MMP-1 was observed
in the synovial sublining (Figure 8, upper panels), while
RasGRF1 colocalization with MMP-3 was restricted to the inti-
mal lining layer (Figure 8, lower panels). Together, these data
indicate that RasGRF1 may contribute to RA FLS MMP-3 pro-
duction in vivo.
Figure 5
Effect of RasGRF1 overexpression on rheumatoid arthritis fibroblast-like synoviocyte matrix metalloproteinase and cytokine production Effect of RasGRF1 overexpression on rheumatoid arthritis fibroblast-like synoviocyte matrix metalloproteinase and cytokine production. Tissue cul-
ture supernatants from rheumatoid arthritis fibroblast-like synoviocytes transfected with empty vector or with Ras guanine nucleotide-releasing factor 
1 (RasGRF1) were harvested and assessed for production of (a) matrix metalloproteinase (MMP)-1, (b) TIMP-1, (c) the ratio of TIMP-1 to MMP-1, 
(d) MMP-3, (e) IL-6 (n = 4 each) and (f) IL-8 (n = 3) by ELISA. *P < 0.05 compared with controls.Available online http://arthritis-research.com/content/11/4/R121
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Discussion
Our results demonstrate that RasGRF1 regulates spontane-
ous MMP-3 production in RA FLS, and suggest that overex-
pression of RasGRF1 sensitizes signaling pathways
promoting MMP-3 production and joint destruction in RA.
RasGRF1 specifically activates H-Ras, but not other Ras
homologs  in vivo [28], and RasGRF1 activation of H-Ras
induces constitutive MMP-9 production in human melanoma
cells [27]. RasGRF1 can also activate the Rho family GTPase
Rac1 [29,30], and a role for Rac1 – potentially via activation
of JNK – has been recently shown in the regulation of RA FLS
proliferation and invasiveness [41]. Data have been reported
indicating that RasGRF1 can also stimulate GTP exchange on
R-Ras in vitro, although this GEF activity has yet to be verified
in vivo [42,43].
Our data raise the possibility that changes in the expression of
GEFs, such as RasGRF1, or of negatively regulatory GAPs
may be more relevant to the pathology of RA than GTPase
expression levels. We observe a strong positive correlation
between RasGRF1 expression in RA synovial tissue on the
one hand, and production of MMP-1 and MMP-3 on the other.
Such an association is not clearly observed in non-RA synovial
tissue. Consistent with the notion that RasGRF1 is involved in
the regulation of MMPs, we find that RasGRF1 expression
colocalizes to synovial cells producing MMP-1 and MMP-3 in
situ, and that modulation of RasGRF1 in RA FLS in vitro regu-
lates spontaneous MMP-3 production by these cells. The ina-
bility of RasGRF1 modulation to regulate MMP-1 production in
RA FLS, despite the positive association of expression of
these proteins in the synovial sublining in vivo, may indicate
that other RasGRF1-expressing cells – namely, macrophages
– are a more important source of MMP-1 in vivo. Consistent
with this, we observe a relationship between RasGRF1 and
MMP-1 in the synovial sublining, where macrophages consti-
tute the predominant cell population. Additionally, co-localiza-
tion of cells expressing RasGRF1 and MMP-1 is most
apparent in the synovial sublining layer. Further direct studies
will be needed to examine whether RasGRF1 regulates MMP-
1 production in synovial macrophages. Alternatively,
RasGRF1-dependent secretion of IL-8 or other as yet uniden-
tified inflammatory cytokines may indirectly promote MMP-1
production in vivo through the recruitment and/or activation of
leukocytes.
Figure 6
Effect of RasGRF1 gene silencing on rheumatoid arthritis fibroblast-like synoviocyte matrix metalloproteinase and cytokine production Effect of RasGRF1 gene silencing on rheumatoid arthritis fibroblast-like synoviocyte matrix metalloproteinase and cytokine production.  Tissue cul-
ture supernatants from rheumatoid arthritis fibroblast-like synoviocytes treated with transfection reagent alone (mock) or transfected with control or 
Ras guanine nucleotide-releasing factor 1 (RasGRF1) locked nucleic acid (LNA) were harvested and assessed for production of (a) matrix metallo-
proteinase (MMP)-1, (b) TIMP-1, (c) the ratio of TIMP-1 to MMP-1, (d) MMP-3, (e) IL-6 (n = 4 each) and (f) IL-8 (n = 3) by ELISA. *P < 0.05 com-
pared with controls.Arthritis Research & Therapy    Vol 11 No 4    Abreu et al.
Page 10 of 13
(page number not for citation purposes)
We provide additional in vitro evidence that although many
FLS stimuli regulate both MMP-1 and MMP-3 expression, reg-
ulation of these two proteases is not requisitely coupled. For
instance, adhesion of RA FLS to laminin-111 in the presence
of tumor growth factor beta induces expression of MMP-3 but
not of MMP-1 [44]. Inhibition of JNK can partially block TNFα-
induced MMP-1 production by RA FLS, but MMP-3 produc-
tion is independent of JNK [45]. Reciprocally, mitogen-acti-
vated protein kinase-activated protein kinase 2 (MK2)
regulates MMP-3 secretion, but not MMP-1, in OA chondro-
cytes [46]. The fact that regulation of MMP-1 is uncoupled
from that of MMP-3 probably reflects differential utilization of
NF-κB, activator protein-1 (AP-1), E26 transforming sequence
(Ets), and hypoxia-inducible factor-1α transcription factors by
Figure 7
Association of RasGRF1 expression with matrix metalloproteinase production in rheumatoid arthritis synovial tissue Association of RasGRF1 expression with matrix metalloproteinase production in rheumatoid arthritis synovial tissue. (a) Representative staining of 
rheumatoid arthritis synovial tissue with control and anti-matrix metalloproteinase (MMP)-1, MMP-3, and IL-6 antibodies (magnification × 100). (b) 
Correlation of Ras signaling protein expression with MMP-1 and MMP-3 production in RA synovial tissue. Pearson R values and P values are indi-
cated. IOD, integrated optical density; RasGRF1, Ras guanine nucleotide-releasing factor 1.Available online http://arthritis-research.com/content/11/4/R121
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the promoters of the MMP-1 and MMP-3 genes [42,47,48].
Similarly, we find that RasGRF1 is necessary for spontaneous
IL-6 production by RA FLS, but overexpression of RasGRF1 is
not sufficient to augment IL-6 secretion. This may reflect a nec-
essary coordination of RasGRF1 signaling with other signaling
pathways, such as previously reported cooperative effects
between Ras GTPase and c-myc pathways in the regulation of
RA FLS activation [22]. Further definition of pathways by
which RasGRF1 modulates MMP and cytokine production will
require identification of the immediate downstream target(s) of
this GEF in FLS.
While RasGRF1 expression is sufficient and required for
spontaneous MMP-3 production in RA FLS, similar effects of
RasGRF1 on MMP-1, TIMP-1 and IL-6 are not observed. Stim-
uli that activate RasGRF1 include ligands for both tyrosine
kinase receptors and G-protein-coupled receptor [49]. Exam-
ples of receptors known to regulate RasGRF1 and expressed
in RA synovial tissue include those for lysophosphatidic acid
and muscarinic acid, N-methyl-D-aspartic acid, and nerve
growth factor [50-53]. In preliminary studies, we have found
that silencing of RasGRF1 in RA FLS has no effect on TNFα-
induced or IL-1β-induced MMP-3 production (data not
shown). RasGRF1 activity can also be regulated by post-
translational modification, as calpain-dependent cleavage of
RasGRF1 enhances Ras-activating capacity in vitro and in
vivo [27,31]. Enhanced expression of RasGRF1 in RA tissue
compared with non-RA tissue may sensitize RA FLS to pro-
duce MMPs in response to extracellular stimuli. This would
result from disease-specific extracellular stimuli activating full-
length RasGRF1, as well as constitutive signaling from post-
translationally modified RasGRF1, such as the predominantly
expressed 96 kDa carboxy-terminal fragment we observe in
synovial tissue. Identification of the protease(s) responsible for
RasGRF1 cleavage in vivo may lead to new therapeutic strat-
egies in the treatment of arthritis.
Conclusions
RasGRF1 expression and post-translational modifications reg-
ulate spontaneous MMP-3 production in RA FLS, and are
associated with MMP-3 production in RA synovial tissue. Con-
tributions of RasGRF1 to MMP-3 production in RA and other
forms of arthritis will probably depend on RasGRF1 expres-
sion levels, on the extent of activating post-translational modi-
fications of RasGRF1, and on the strength of extracellular
stimuli leading to activation of residual full-length RasGRF1.
Our data suggest a molecular mechanism by which Ras sign-
aling pathways might contribute to the semi-transformed and
invasive phenotype of RA FLS in the absence of oncogenic
mutations in Ras superfamily GTPases.
Figure 8
Double immunofluorescence labeling of RasGRF1, MMP-1 and MMP-3 in rheumatoid arthritis synovial tissue Double immunofluorescence labeling of RasGRF1, MMP-1 and MMP-3 in rheumatoid arthritis synovial tissue. Rheumatoid arthritis synovial tissue 
was stained with combinations of anti-Ras guanine nucleotide-releasing factor 1 (anti-RasGRF1) and either anti-matrix metalloproteinase (MMP)-1 
(upper panels) or anti-MMP-3 (lower panels). Sections were then stained with fluorochrome-conjugated anti-rabbit immunoglobulin (red) and anti-
mouse IgG (green) antibodies to visualize RasGRF1 and MMP expression, respectively. Colocalization of RasGRF1 with MMPs is visualized by yel-
low staining in merged images (right panels).Arthritis Research & Therapy    Vol 11 No 4    Abreu et al.
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